

The global wound gel market size was valued at USD 6.05 billion in 2024 and is projected to reach USD 9.68 billion by 2033, growing at a CAGR of 5.37% from 2025 to 2033. The demand for wound gel is rising owing to the increasing number of surgical cases and the growing burden of wounds.
The rising number of surgical procedures worldwide is a significant driver for expanding the wound gels market. Surgical interventions often result in acute wounds that require effective post-operative care to minimize infection risk and promote faster healing. Advanced wound care products, particularly wound gels, are increasingly preferred due to their ability to maintain a moist wound environment, support autolytic debridement, and accelerate tissue regeneration. According to data published in the BMC Surgery journal in 2025, approximately 313 million surgical procedures are performed globally annually. This substantial volume underscores the growing demand for reliable and effective wound care solutions, reinforcing the critical role of wound gels in the post-surgical healing process.
List of Key Players in the Wound Gel Market
Medline Industries, LP.
Coloplast Ltd
Mölnlycke Health Care AB
Solventum
Convatec Inc.
Smith+Nephew
B. Braun SE
DermaRite Industries, LLC.
Integra LifeSciences Corporation
Axio Biosolutions Private Limited
Sanara MedTech Inc
Request a free sample copy or view report summary: Wound Gel Market
Wound Gel Market Report Highlights
The dressings segment dominated the wound gel industry in 2024, driven by continuous innovation in advanced materials such as hydrogel, gelling fiber, and specialty formulations like honey and silicone gel dressings.
The silver (Ag+) segment held the largest market share in 2024 within the antimicrobial properties segment, demonstrating its leading role in advanced wound care. It is also anticipated to grow fastest over the forecast period.
The chronic wounds segment dominated the market in 2024, capturing the largest share of 55.29%. This dominance is attributed to the high prevalence and significant healthcare burden associated with chronic wounds.
The offline segment held the largest market share in 2024. This dominance is primarily attributed to the widespread availability of wound gel products through hospitals, pharmacies, and medical supply stores, where healthcare professionals often guide product selection.
The hospital segment dominated the market in 2024, accounting for the largest share of 41.52%. This dominance is due to the high volume of patients requiring advanced wound care for acute and chronic conditions.
Wound Gel Market Segmentation
Grand View Research has segmented the global wound gel market report based on product, antimicrobial properties, application, mode of purchase, distribution channel, end use, and region:
Product Outlook (Revenue, USD Million, 2021 - 2033)
Dressings
- Hydrogel dressing
- Gelling fiber dressings
- Others
Gels
Antimicrobial Properties Outlook (Revenue, USD Million, 2021 - 2033)
Silver (Ag+)
Non-Silver
Mode of Purchase Outlook (Revenue, USD Million, 2021 - 2033)
Prescription
Non-prescription
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Offline
Online
Application Outlook (Revenue, USD Million, 2021 - 2033)
Chronic Wounds
- Diabetic Foot Ulcers (DFUs)
- Pressure Ulcers
- Stage 1
- Stage 2
- Stage 3
- Stage 4
- Leg Ulcers
Acute Wounds
- Surgical Incisions
- Burns
1st Degree
2nd Degree
3rd Degree
- Lacerations, Abrasions
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Specialty Clinics
- Ambulatory Surgery Centers
- Homecare Settings
- Long-Term Care Facilities
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Recent Developments
- In March 2025, SolasCure announced the enrollment of the first patient in its upcoming Phase II clinical trial to advance the development of the Aurase Wound Gel. This marks a significant milestone in the company’s efforts to evaluate the safety and efficacy of the gel in promoting wound healing. The trial is designed to gather critical data supporting further clinical development and potential regulatory approval of this innovative treatment.
- In March 2025, Mölnlycke Health Care completed the acquisition of the manufacturer of Granudacyn. Granudacyn includes solutions and gels designed explicitly for wound cleansing, irrigation, and moisturizing across various wound types. This strategic acquisition strengthens Mölnlycke’s portfolio, enhancing its capabilities to deliver comprehensive and effective solutions for wound care and infection prevention.





